The Business Times
business-time-50

Novo Nordisk

Opinion & Features
THINKING ALOUD

A GLP-1 tsunami is headed for the vice industry. Good.

India is the first major market to see a flood of copycat semaglutide medications.
Consumer & Healthcare

Low-cost Ozempic copies launch in India as Novo Nordisk’s patent expires

The deals include agreements with Eli Lilly and Novo Nordisk to slash the prices of popular GLP-1 weight-loss drugs.
International

Trump unveils TrumpRx discounted drugs website

Jay Thyagarajan, senior VP for Apac at Novo Nordisk, says that one way the company intends to manage patent expiries is through continued investments in R&D, including work on novel drug formulations.
Companies & Markets
TOPLINE

‘Treating obesity for the next 100 years’: Ozempic-maker Novo Nordisk targets tripling of Apac patient base

Under a November deal with the Trump administration, Novo agreed to sell starter doses of their weight-loss pills if approved.
Consumer & Healthcare

Novo Nordisk shares jump almost 8% after US approves Wegovy pill

Pop Mart, the Chinese firm behind Labubu dolls (above), is battling a scourge of fake Lafufus that have flooded online marketplaces.
Opinion & Features
PERSPECTIVE

What Novo Nordisk, OpenAI and Pop Mart have in common

Novo chief executive officer Mike Doustdar has been pushing to rebuild momentum in the company’s pipeline following intense competition in the weight-loss drug market.
Companies & Markets

Novo gets 15 billion euros of orders for Akero acquisition bonds

Pfizer said it would pay US$86.25 per share in cash, a premium of 3.69 per cent to Metsera’s Friday close.
Companies & Markets

Metsera accepts Pfizer’s US$10 billion bid in ongoing M&A battle

Novo Nordisk became Europe’s most valuable firm from rapid sales growth of its blockbuster obesity drug Wegovy, but has seen sales growth slow
International

Novo Nordisk lowers full-year profit guidance in new CEO’s maiden quarter

The tussle for Metsera began with discussions between the company and potential acquirers in early 2024, with both Pfizer and Novo Nordisk, the maker of Wegovy and Ozempic, expressing interest.
Companies & Markets

Pfizer sues Metsera, Novo Nordisk over rival obesity drug bid

Latest T-bills Treasury Bills Results & Interest NewsLatest SSB Singapore Savings Bonds NewsLatest COE Certificate of Entitlement News
Latest Johor-Singapore SEZ NewsLatest BTO Build To Order & Sales of Balance NewsLatest STI Straits Times Index NewsLatest SGX Dividends, Share Price NewsLatest Bonds Market NewsLatest Singapore Stocks To Buy NewsLatest Singapore Economy News
View More